Drugmakers look to repurposed meds for COVID-19 therapeutics by Kyle Blankenship, Fraiser Kansteiner Wednesday, March 25, 2020 With drugmakers on the hunt for COVID-19 therapeutic, could one of a range of repurposed meds offer a solution? We run down the latest options.
Chloroquine, Kaletra and a flu drug disappoint in COVID-19 tests by Angus Liu Tuesday, March 24, 2020 All three drugs are included in China's COVID-19 treatment guidelines, and one was just highlighted by President Trump.
AbbVie gives up Kaletra rights amid COVID-19 tests: report by Kyle Blankenship Monday, March 23, 2020 AbbVie has reportedly given up its global rights to Kaletra, an HIV med in clinical trials evaluating it against COVID-19.
AbbVie CEO secured $21.6M pay package in 2019 amid megamerger by Kyle Blankenship Monday, March 23, 2020 AbbVie CEO Rick Gonzalez had a busy year with Humira sales abroad down and a $63 billion merger under review, but that work didn't much alter his pay.
AbbVie, Roche's Venclexta nails confirmatory combo trial in AML by Kyle Blankenship Monday, March 23, 2020 Weeks after a Venclexta-chemo combo flopped a confirmatory trial in acute myeloid leukemia, a second combo hit its marks in a separate study.
Inside Regeneron, shared urgency drives COVID-19 efforts by Kyle Blankenship Friday, March 20, 2020 Through weeks of sleepless nights and conference calls, Regeneron's research team is well positioned to solve COVID-19 with regulators' backing.
Biogen, Bayer rogue staffers; Kaletra and more—FiercePharmaAsia by Angus Liu Friday, March 20, 2020 Biogen and Bayer deal with coronavirus rule-breakers in China. AbbVie's Kaletra fails COVID-19 study. Fosun licenses BioNTech's coronavirus vaccine.
AbbVie's HIV drug Kaletra fails in COVID-19 trial—or does it? by Angus Liu Thursday, March 19, 2020 A team of Chinese scientists found Kaletra offered little benefit to COVID-19 patients, but one analyst refuses to call it a dead end.
AbbVie, Allergan deal may face delay due to COVID-19: report by Kyle Blankenship Tuesday, March 17, 2020 With only the Federal Trade Commission left to clear in their $63 billion merger, AbbVie and Allergan may face a delay due to the novel coronavirus.
J&J warns doctors off using HIV med Prezista for COVID-19 by Kyle Blankenship Tuesday, March 17, 2020 With drugmakers on the hunt for a COVID-19 therapeutic, Johnson & Johnson said repurposing HIV med Prezista might not do the trick.
